<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37954002</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-7762</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet regional health. Europe</Title><ISOAbbreviation>Lancet Reg Health Eur</ISOAbbreviation></Journal><ArticleTitle>Determinants of the onset and prognosis of the post-COVID-19 condition: a 2-year prospective observational cohort study.</ArticleTitle><Pagination><StartPage>100724</StartPage><MedlinePgn>100724</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100724</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lanepe.2023.100724</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">At least 5-10% of subjects surviving COVID-19 develop the post-COVID-19 condition (PCC) or "Long COVID". The clinical presentation of PCC is heterogeneous, its pathogenesis is being deciphered, and objective, validated biomarkers are lacking. It is unknown if PCC is a single entity or a heterogeneous syndrome with overlapping pathophysiological basis. The large US RECOVER study identified four clusters of subjects with PCC according to their presenting symptoms. However, the long-term clinical implications of PCC remain unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a 2-year prospective cohort study of subjects surviving COVID-19, including individuals fulfilling the WHO PCC definition and subjects with full clinical recovery. We systematically collected post-COVID-19 symptoms using prespecified questionnaires and performed additional diagnostic imaging tests when needed. Factors associated with PCC were identified and modelled using logistic regression. Unsupervised clustering analysis was used to group subjects with PCC according to their presenting symptoms. Factors associated with PCC recovery were modelled using a direct acyclic graph approach.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">The study included 548 individuals, 341 with PCC, followed for a median of 23 months (IQR 16.5-23.5), and 207 subjects fully recovered. In the model with the best fit, subjects who were male and had tertiary studies were less likely to develop PCC, whereas a history of headache, or presence of tachycardia, fatigue, neurocognitive and neurosensitive complaints and dyspnea at COVID-19 diagnosis predicted the development of PCC. The cluster analysis revealed the presence of three symptom clusters with an additive number of symptoms. Only 26 subjects (7.6%) recovered from PCC during follow-up; almost all of them (n&#xa0;=&#xa0;24) belonged to the less symptomatic cluster A, dominated mainly by fatigue. Recovery from PCC was more likely in subjects who were male, required ICU admission, or had cardiovascular comorbidities, hyporexia and/or smell/taste alterations during acute COVID-19. Subjects presenting with muscle pain, impaired attention, dyspnea, or tachycardia, conversely, were less likely to recover from PCC.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">Preexisting medical and socioeconomic factors, as well as acute COVID-19 symptoms, are associated with the development of and recovery from the PCC. Recovery is extremely rare during the first 2 years, posing a major challenge to healthcare systems.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">Fundaci&#xf3; Lluita contra les Infeccions.</AbstractText><CopyrightInformation>&#xa9; 2023 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mateu</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Vic - UCC, Vic, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>REICOP, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tebe</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biostatistics Unit, Hospital Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol, Can Ruti Campus, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loste</LastName><ForeName>Cora</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Vic - UCC, Vic, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>REICOP, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Jos&#xe9; Ram&#xf3;n</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llad&#xf3;s</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>REICOP, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espa&#xf1;a-Cueto</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toledo</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Font</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chamorro</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz-L&#xf3;pez</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nevot</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallejo</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teis</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puig</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fumaz</LastName><ForeName>Carmina R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>REICOP, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz-Moreno</LastName><ForeName>Jos&#xe9; A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>REICOP, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estany-Quera</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coll-Fern&#xe1;ndez</LastName><ForeName>Roser</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>REICOP, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rehabilitation, Hospital Germans Trias i Pujol, Can Ruti Campus, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrero</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casares</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clotet</LastName><ForeName>Bonaventura</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Vic - UCC, Vic, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Infectious Diseases (CIBERINFEC), Institute of Health Carlos III (ISCIII), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Vic - UCC, Vic, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Infectious Diseases (CIBERINFEC), Institute of Health Carlos III (ISCIII), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massanella</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>REICOP, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Infectious Diseases (CIBERINFEC), Institute of Health Carlos III (ISCIII), Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health Eur</MedlineTA><NlmUniqueID>101777707</NlmUniqueID><ISSNLinking>2666-7762</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID-19</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 condition</Keyword></KeywordList><CoiStatement>LM has received grants from Grifols, honoraria as speaker from Astra-Zeneca, Gilead, and Pfizer, and has participated in advisory boards for Gilead and MSD. CL has received support for attending meetings from Gilead. AG has received grants from Grifols, honoraria for lectures or presentations from Astra-Zeneca, Gilead, and Pfizer, and has participated on DSMB or advisory boards for Gilead and MSD. RP has participated in advisory boards for Pfizer, Gilead, MSD, GSK, Atea, Lilly, Roche, Astra-Zeneca, ViiV Healthcare and Theratechnologies, has participated in lectures and seminars funded by Gilead, Pfizer, GSK and AstraZeneca, and has received research funds awarded to his institution from Gilead, Pfizer, and MSD. MM has received honoraria for participating in lectures and seminars funded by Gilead. MM was granted with RYC2020-028934-I/AEI/10.13039/501100011033 from Spanish Ministry of Science and Innovation and State Research Agency and the European Social Fund &#x201c;investing in your future&#x201d;. This work had the additional collaboration of &#x201c;Programa de Becas Gilead a la Investigaci&#xf3;n Biom&#xe9;dica, GLD21_00070&#x201d;. FM was supported by Sorigu&#xe9; Foundation. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>13</Day><Hour>4</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37954002</ArticleId><ArticleId IdType="pmc">PMC10636281</ArticleId><ArticleId IdType="doi">10.1016/j.lanepe.2023.100724</ArticleId><ArticleId IdType="pii">S2666-7762(23)00143-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wynants L., Van Calster B., Collins G.S., et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ. 2020;369:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222643</ArticleId><ArticleId IdType="pubmed">32265220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A.V., van Zon S.K.R., olde Hartman T.C., Rosmalen J.G.M. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400:452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis R.H., Santillana M., Ognyanova K., et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. 2022;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kim S.S., Lindsell C.J., et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network &#x2014; united. MMWR Morb Mortal Wkly Rep. 2020;69:993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade B.S., Siqueira S., de Assis Soares W.R., et al. Long-covid and post-covid health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021;13:700. doi: 10.3390/v13040700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13040700</ArticleId><ArticleId IdType="pmc">PMC8072585</ArticleId><ArticleId IdType="pubmed">33919537</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigfrid L., Drake T.M., Pauley E., et al. Long covid in adults discharged from UK hospitals after Covid-19: a prospective, multicentre cohort study using the ISARIC WHO clinical characterisation protocol. Lancet Reg Health Eur. 2021 doi: 10.1016/j.lanepe.2021.100186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100186</ArticleId><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC)  Long COVID or post-COVID conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html</Citation></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence . NICE; 2021. COVID-19 rapid guideline.</Citation><ArticleIdList><ArticleId IdType="pubmed">33497154</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet T. Facing up to long COVID. Lancet. 2020;396:1861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834723</ArticleId><ArticleId IdType="pubmed">33308453</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation (WHO)   2021. A&#xa0;clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021.https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation></Reference><Reference><Citation>Thaweethai T., Jolley S.E., Karlson E.W., et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329:1934&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradenas E., Trinit&#xe9; B., Urrea V., et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med. 2021;2:313&#x2013;320.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847406</ArticleId><ArticleId IdType="pubmed">33554155</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinit&#xe9; B., Pradenas E., Marfil S., et al. Previous sars-cov-2 infection increases b.1.1.7 cross-neutralization by vaccinated individuals. Viruses. 2021;13:1135. doi: 10.3390/v13061135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061135</ArticleId><ArticleId IdType="pmc">PMC8231627</ArticleId><ArticleId IdType="pubmed">34204754</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap)&#x2014;a metadata-driven methodology and workflow process for providing translational research informatics support. J&#xa0;Biomed Inform. 2009;42:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin P.C., Tu J.V. Bootstrap methods for developing predictive models. Am Stat. 2004;58:131&#x2013;137.</Citation></Reference><Reference><Citation>Rothman K.J., Greenland S., Lash T.L. Wolters Kluwer Health/Lippincott Williams &amp; Wilkins; Philadelphia: 2008. Modern epidemiology.</Citation></Reference><Reference><Citation>R Core Team  . R Found. Stat. Comput.; Vienna, Austria: 2021. R: a language and environment for statistical com-puting.https://www.r-project.org</Citation></Reference><Reference><Citation>Subirana I., Sanz H., Vila J. Building bivariate tables: the compareGroups package for R. J&#xa0;Stat Softw. 2014;57:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Maechler M., Rousseeuw P., Struyf A., Hubert M., Hornik K. 2012. Cluster: cluster analysis basics and extensions.</Citation></Reference><Reference><Citation>L&#xfc;decke D., Ben-Shachar M.S., Patil I., Waggoner P., Makowski D. performance: an R package for assessment, comparison and testing of statistical models. J&#xa0;Open Source Softw. 2021;6:3139.</Citation></Reference><Reference><Citation>Peluso M.J., Deeks S.G. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 2022;43:268&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D., Martino L., Morello R., Mariani F., Fearnley K., Valentini P. Viral persistence in children infected with SARS-CoV-2: current evidence and future research strategies. Lancet Microbe. 2023 doi: 10.1016/S2666-5247(23)00115-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00115-5</ArticleId><ArticleId IdType="pmc">PMC10292824</ArticleId><ArticleId IdType="pubmed">37385286</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein S.R., Ramelli S.C., Grazioli A., et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z., Senussi Y., Manickas-Hill Z., et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76:e487&#x2013;e490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A., McAuley H., Harrison E.M., et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9:1275&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A., Leavy O.C., Richardson M., et al. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10:761&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G., Mccann K., Brien C.O., et al. Identification of distinct long COVID clinical phenotypes through cluster analysis of self-reported symptoms. Open Forum Infect Dis. 2022;9(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8900926</ArticleId><ArticleId IdType="pubmed">35265728</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida T., Yoshimura N., Ishizuka K., Katayama K., Inoue Y., Hirose M. Five cluster classifications of long COVID and their background factors: a cross - sectional study in Japan. Clin Exp Med. 2023 doi: 10.1007/s10238-023-01057-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-023-01057-6</ArticleId><ArticleId IdType="pmc">PMC10081305</ArticleId><ArticleId IdType="pubmed">37027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:1&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello R., Mariani F., Mastrantoni L., et al. Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study. EClinicalMedicine. 2023;59</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101848</ArticleId><ArticleId IdType="pubmed">37073325</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams T.C., Bach C.C., Matthiesen N.B., Henriksen T.B., Gagliardi L. Directed acyclic graphs: a tool for causal studies in paediatrics. Pediatr Res. 2018;84(4):487&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6215481</ArticleId><ArticleId IdType="pubmed">29967527</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Kulzhabayeva D., Rodrigues N.B., et al. COVID-19 vaccination for the prevention and treatment of long COVID: a systematic review and meta-analysis. Brain Behav Immun. 2023;111:211&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10067136</ArticleId><ArticleId IdType="pubmed">36990297</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>